Melbourne researchers have identified a gene mutation in the leukaemia cells of patients who become resistant to venetoclax, a discovery which can be used to identify those at-risk of relapse and help improve outcomes from this breakthrough blood cancer drug.
Peter Mac researchers have found a way to predict which patients with locally advanced rectal cancers might be diverted into a “watch and wait” group, potentially avoiding the need for lower bowel removal surgery and its life-long consequences.
Today we recognised the generosity of the Australian Cancer Research Foundation (ACRF) for their $2m research grant which has provided researchers from Peter Mac and our VCCC partners with cutting edge tech which will help them break new ground in cancer research.
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.